–
CEO Pnina Fishman / Ilan Besor
–
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Can-Fite BioPharma Ltd. ( CANF ) announced today that the Phase 3 trial carried out by its subsidiary OphthaliX Inc. (OPLI.PK) of its drug CF101on patients with moderate-to-severe Dry Eye Syndrome was unsuccessful.
The trial did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the secondary efficacy endpoints. CF101 was found to be well tolerated.
“We are disappointed from the fact that the phase 3 clinical trial for the treatment of Dry Eye Syndrome did not meet the endpoints. We intend to learn the trial results and extract from the clinical data received the lessons required for the successful advancement of Can-Fite’s compounds in various indications. The fact that the safety profile of CF101 remains high and is consistent is very encouraging and emphasizes an important advantage of CF101 compared to other drugs on the market. We believe in the platform technology and will continue to develop it for the appropriate indications, ” said Pnina Fishman, CEO of Can-Fite.
Last week, the company reported success in a Phase 2b trial of CF101 as a treatment for rheumatoid arthritis.
–
